CLINICAL_TRIALS
ClinicalTrials.gov record update
A Phase 2 Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, in Adults and Children With PIK3CA Related Overgrowth Spectrum and Malformations Driven by PIK3CA Mutation
This page presents selected fields from the linked source record. It does not add a medical interpretation.
Record identity and dates
- Source
- ClinicalTrials.gov
- Source record ID
- NCT06789913
- Title field or adapter rule
- protocolSection.identificationModule.officialTitle
- Ingested At
- 2026-04-25T22:28:40.800394+00:00
- Published At
- 2026-01-08T00:00:00+00:00
- Record Updated At
- 2026-01-08
- Timestamp Basis
- source retrieval time was not retained by the feed adapter
- Date limitation
- source retrieval time was not retained by the feed adapter
Fields recorded by this source
- protocolSection.conditionsModule.conditions
["PIK3CA-Related Overgrowth Spectrum (PROS)", "Lymphatic Malformations", "Vascular Malformations", "PIK3CA Mutation", "CLOVES Syndrome", "Klippel Trenaunay Syndrome", "Megalencephaly-capillary Malformation Polymicrogyria Syndrome (MCAP)"]- protocolSection.statusModule.lastUpdatePostDateStruct.date
"2026-01-08"- protocolSection.identificationModule.nctId
"NCT06789913"- protocolSection.identificationModule.officialTitle
"A Phase 2 Study of Mutant-selective PI3K\u03b1 Inhibitor, RLY-2608, in Adults and Children With PIK3CA Related Overgrowth Spectrum and Malformations Driven by PIK3CA Mutation"- protocolSection.statusModule.overallStatus
"RECRUITING"- protocolSection.designModule.phases
["PHASE2"]- protocolSection.statusModule.resultsFirstPostDateStruct.date
""
Study condition terms
Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.
This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.